Special Issue "Bacteriophages as Therapeutic Delivery Vehicles"
Deadline for manuscript submissions: 30 July 2021.
Interests: bacteriphage; host range; phage therapy; phage ecology
Interests: bacteriophage; transduction; antibiotic resistance; phage therapeutics
Bacteriophages and other viruses can be considered highly evolved gene delivery vehicles that carry their genome payloads in metabolically inert virion particles between host cells. For many tailed bacteriophages, simply binding to the host cell receptor triggers a complex series of protein conformational changes that lead to the injection of the phage genome into the host cell. Other viruses rely on host cell endocytosis mechanisms that are activated upon binding of the viruses to cell receptors. While in most cases, these mechanisms lead to the viral genome entering the cell as part of the infection process, there are cases when the nucleic acids being delivered are not the viral genome. Probably the best known example of this is generalized transduction, in which a fragment of the host genome instead of the viral genome is packaged into a phage particle and the particle carries that fragment to another host cell where the DNA can be retained via recombination.
Many clever researchers have developed techniques to replace the virus genome in the virion particle with a virus genome that has non-virus genes or an entirely non-virus segment of nucleic acid. The applications of these genetically modified viruses can be quite varied including:
- Targeted delivery of toxin genes to kill cells
- Targeted delivery of genes encoding desirable traits to modify cellular function
- Gene therapy
- Phage vaccines
A related but very different use of virus particles is the attachment of toxins or other therapeutic molecules to the outside of the virus capsid, again using the receptor binding protein affinity for the cell receptor to direct the payload to the correct cells.
For this Special Issue, we invite authors to submit articles providing examples of the various uses of bacteriophages and other viruses to deliver some non-virus gene or molecule. Reviews, proposals and research reports are all welcome.
Prof. Paul Hyman
Dr. Christine Schneider
Dr. Bryan Gibb
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Phage therapy
- Gene therapy
- Phage-mediated biocontrol
- Gene transfer agent
- Therapeutic genes
- Genome modification